Losartan Potassium
Product Images NDC 45865-687

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 45865-687). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (687)

Losartan Potassium 25mg tablets packaging label from Medsource Pharmaceuticals, generic for Cozaar. The white oval film-coated tablets are in a blister pack, with product NDC 45865-0687-49 and a quantity of 100 tablets. The label includes warnings about dizziness and alcohol use, advising consultation with a doctor if pregnant.*

FDA Label Image

Figure 1 (92296151 E507 41b4 A040 C01b87ecb982 01)

Chemical structure of Losartan Potassium, showing its molecular framework including a chlorinated pyrimidine ring, biphenyl group, and potassium ion.*

FDA Label Image

Figure 2 (92296151 E507 41b4 A040 C01b87ecb982 02)

A line graph comparing the percentage of patients reaching the primary endpoint over study months for Atenolol (dotted line) and Losartan Potassium Tablets (solid line). The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients up to 16%. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium Tablets compared to Atenolol.*

FDA Label Image

Figure 3 (92296151 E507 41b4 A040 C01b87ecb982 03)

A line graph comparing the percentage of patients with fatal/non-fatal stroke over study months for Atenolol (dotted line) and Losartan Potassium tablets (solid line). The chart highlights an adjusted risk reduction of 25% with a statistical significance of p=0.001.*

FDA Label Image

Figure 4 (92296151 E507 41b4 A040 C01b87ecb982 04)

A forest plot depicting primary composite and stroke (fatal/non-fatal) event hazard ratios comparing Losartan Potassium Tablets to Atenolol. It shows subgroup analyses by age, gender, race, ischemic heart status, diabetes, and cardiovascular disease history with event rates and 95% confidence intervals, illustrating comparative risks between treatments.*

FDA Label Image

Figure 5 (92296151 E507 41b4 A040 C01b87ecb982 05)

A Kaplan-Meier curve chart comparing the percentage of patients with event over 48 months between Losartan Potassium Tablets and placebo. The chart shows a 16.1% risk reduction with a reported p-value of 0.022, indicating a statistically significant difference in event occurrence over time.*

FDA Label Image

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 06)

FDA Label Image

Figure 6 (92296151 E507 41b4 A040 C01b87ecb982 07)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.